Biological thiols on the surface of activated T cells may provide a localized target for immunotherapy.[9, 12] Additionally, nanoclusters have been designed to release programmed cell death protein 1 (PD‐1) antibodies in the TME,[13, 14, 15] enhancing the efficacy of adoptive T cell cancer therapy while reducing its side effects.[16, 17] However, these immune stimulators rely on endogenous stimuli, which may not be sufficient to enable a controllable release of the drug. This evidence concerns the gene PDCD1 and cancer.